YSYanhan Shen

Yanhan Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yanhan Shen has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Kidney function parameters in South African children living with HIV on antiretroviral therapy

    by Yanhan Shen, Elliott Y. Huang, Olivia Yin, Stephanie Shiau, Renate Strehlau, Faeezah Patel, Louise Kuhn, Fangming Lin, Stephen M. Arpadi

    Background: We evaluated longitudinal kidney function in children with perinatally acquired HIV (CWH) compared with HIV-negative controls. Methods: We analyzed data from an observational study in Johannesburg, South Africa (2013–2018), including 220 CWH on non–tenofovir regimens and 220 controls. Baseline and follow-up visits with blood, urine, and dual-energy X-ray absorptiometry (DXA) were conducted a median of 3.7 years apart. Kidney function was assessed using serum creatinine-based (revised bedside Schwartz equation) and cystatin C–based (univariate CKiD cystatin C equation) estimated glomerular filtration rates (eGFR) and urinary microalbuminuria, proteinuria, and β 2 -microglobulin. We assessed between-group differences stratified by sex. Multivariable logistic regression was utilized to identify factors associated with microalbuminuria and proteinuria. Results: At baseline, mean age was 6.4 years among CWH and 7.0 years among controls. At baseline, the cohort included 220 CWH and 220 controls; 49.1% of CWH and 54.6% of controls were male. Among the 190 CWH and 111 controls who completed follow-up, 48.9% of CWH and 60.3% of controls were male. CWH had lower lean mass, and higher mean creatinine- and cystatin-C based eGFR than controls. Rate of change in eGFR did not differ between CWH and controls during follow-up. An eGFR 90 mL/min/1.73m 2 in all children with proteinuria. Female sex was associated with higher odds of microalbuminuria (aOR 5.39, 95% CI 1.26–37.25) and proteinuria (aOR 2.59, 95% CI 1.44–4.76). Conclusions: Among early treated children with perinatally acquired HIV on non–tenofovir regimens, eGFR was higher than in HIV negative controls, while annualized eGFR change and most urine biomarkers were similar by HIV status. However, a substantial proportion of both groups had eGFR below 90 mL/min/1.73 m 2 and abnormal urinary markers, and male CWH had a higher prevalence of proteinuria than male controls; these findings suggest that a portion of the population have signs of abnormal kidney function that warrant further investigation and monitoring.

  • Open Access

    Long COVID longitudinal symptoms burden clusters within a national community-based cohort

    by Yanhan Shen, Zach Shahn, McKaylee M. Robertson, Kelly Gebo, Denis Nash

    Long COVID is clinically heterogeneous, with evolving symptom trajectories that complicate classification. Prior clustering studies often rely on Electronic Health Records data, risking underreporting. We examined longitudinal, community-based symptom clusters and associated factors. We analyzed CHASING COVID Cohort participants with confirmed SARS-CoV-2 infection between December 2020 and December 2022, ≥ 12 months of follow-up, and long COVID (≥ 1 new symptom and concurrent activity limitation 3-12 months post-infection, both absent pre-infection). The infection in this window was the index infection; those with pre-index long COVID were excluded. Symptoms were self-reported pre-infection and at ~ 3, 6, 9, and 12 months. Missing data were handled via multiple imputation by chained equations (30 datasets). Longitudinal K-means clustering was performed within each imputed dataset, with hierarchical aggregation to derive final assignments. Logistic regression (age- and sex-adjusted) assessed associations of demographic, clinical, and social factors with cluster membership. Within the highest-burden cluster, hierarchical clustering identified symptom phenotypes. Of 1,787 infected participants, 511 met criteria (22% ≥50 years; 55% female; 60% White non-Hispanic; 54% mental health disorder; 7.2% immunodeficiency; 21% ≥2 comorbidities). Three longitudinal clusters emerged: highest, moderate, and lowest burden. The highest-burden cluster showed persistent multisystem symptoms (median 6 symptoms at 6-9 months) with frequent fatigue, concentration difficulty, post-exertional malaise, myalgia, sleep disturbance, gastrointestinal symptoms, headache, irritability, and mobility limitations. The moderate cluster peaked at 3 symptoms, while the lowest remained at 1 symptom. Older age (aOR 2.68, 95% CI 1.59-4.53), female sex (2.36, 1.48-3.76), mental health disorder (2.65, 1.65-4.25), and immunodeficiency (4.23, 1.71-10.51) were associated with highest vs. lowest burden. Within the highest-burden cluster, three phenotypes emerged: multisystemic dysfunction, psychiatric/neurological dysfunction, and physical/respiratory dysfunction. Distinct long COVID clusters and phenotypes underscore heterogeneity and support tailored management and risk stratification.


  • Open Access

    The role of institutional trust in shaping the relationship between vaccine concerns and ongoing COVID-19 vaccination in a US national cohort

    by Jenna Sanborn, Angela Parcesepe, Rachael Piltch-Loeb, Kate Penrose, Yanhan Shen, Andrew Maroko, Denis Nash, McKaylee Robertson

    Concerns about vaccine safety and efficacy and institutional trust are well-established determinants of vaccine uptake, yet little is known about the extent to which institutional trust buffers or amplifies the behavioral effects of vaccine-related uncertainty. Using data from 4,253 adults in the CHASING COVID Cohort who completed their primary vaccine series, we examined whether trust in public health institutions or healthcare providers modified the association between vaccine concerns and receipt of an additional COVID-19 vaccine dose. Adjusted log-binomial regression models estimated risk ratios (aRRs) and 95% CIs, with effect modification assessed on multiplicative and additive scales. The association between not endorsing vaccine concerns and continued vaccination was stronger among those without trust in public health institutions (aRR = 2.38 [95% CI, 1.90-2.97]) than among those with trust (aRR = 1.34 [95% CI, 1.22-1.46]), while antagonism on the additive scale (RERI = $-$0.68; P <.01) indicated overlapping pathways as having no vaccine concerns added little to the likelihood of continued vaccination among those with trust in public health institutions. Provider trust showed modest additive effects (RERI = 0.16; P = .08), suggesting greater-than-additive influences. Together, findings highlight institutional trust as an important contextual determinant shaping how vaccine-related beliefs are enacted and underscoring its importance for promoting ongoing vaccination uptake.


  • Open Access

    Effect of a Third COVID-19 Vaccine Dose on the Incidence of Long COVID Among Adults Who Completed a Primary Vaccine Series: a Target Trial Emulation in a Community-Based Cohort

    by Yanhan Shen, Zach Shahn, Mckaylee Robertson, Kelly Gebo, Denis Nash

    Background Evidence on whether a third COVID-19 vaccine dose lowers long COVID risk is mixed. We estimated the effect of receiving ≥1 third dose versus completing only a primary series on 6- and 12-month long COVID incidence using a target-trial emulation in a U.S. community cohort. Methods We analyzed the CHASING COVID Cohort, a prospective, community-based study of U.S. adults. Eligible participants were ≥18 years, had completed a two-dose primary series, had no prior long COVID, and had no SARS-CoV-2 infection in the 3 months before time zero. Strategies compared were: receive a third dose at time zero vs. not receive a third dose during follow-up. Long COVID was defined as ≥1 new symptom at or beyond 3 months post-infection with concurrent activity limitation, both absent in the prior year. Follow-up was 6 and 12 months. We used a per-protocol analog: participants were artificially censored upon deviating from their assigned strategy or lost-to-follow-up, with inverse-probability weights to address selection due to censoring and time-varying confounding. We fit weighted pooled logistic models to estimate weighted incidence, differences, and ratios at each horizon. Results Across 16 sequential trials (18,930 person-trials; 4,044 unique individuals), 3,321 person-trials received a third dose at time zero and 15,609 did not. At 6 months, weighted long COVID incidence was 0.9% (95% CI, 0.5%, 1.3%) with a third dose vs. 1.0% (0.8%, 1.1%) without (risk difference (RD), −0.1%; 95% CI, −0.5%, 0.4%; risk ratio (RR), 0.93; 95% CI, 0.54, 1.44). At 12 months, incidence was 4.9% (4.1%, 5.9%) with a third dose vs. 4.5% (4.1%, 4.8%) without (RD, 0.4%; 95% CI, −0.5%, 1.4%; RR, 1.09; 95% CI, 0.90, 1.33). Conclusion In this community-based target-trial emulation, receiving a third COVID-19 vaccine dose did not meaningfully reduce 6- or 12-month long COVID incidence compared with completing only a primary series.

  • Open Access

    Long COVID Longitudinal Symptoms Burden Clusters Within A National Community-Based Cohort

    by Yanhan Shen, Zach Shahn, McKaylee M. Robertson, Kelly Gebo, Denis Nash, the CHASING COVID Cohort Study Team

    Background Long COVID is clinically heterogeneous, with evolving symptom trajectories that complicate classification. Prior clustering studies often rely on Electronic Health Records data, risking underreporting. We used longitudinal, community-based data to characterize symptom clusters and risk factors. Methods We analyzed CHASING COVID Cohort participants with confirmed SARS-CoV-2 infection between December 2020 and December 2022, ≥12 months of follow-up, and long COVID (≥1 new symptom and concurrent activity limitation 3–12 months post-infection, both absent pre-infection). The infection in this window was the index infection; those with pre-index long COVID were excluded. Symptoms were self-reported pre-infection and at ∼3, 6, 9, and 12 months. Missing data were handled via multiple imputation by chained equations (30 datasets). Longitudinal K-means clustering was performed within each imputed dataset, with hierarchical aggregation to derive final assignments. Multivariable logistic regression (adjusting for age, sex) assessed associations of demographic, clinical, and social factors with cluster membership. Within the highest-burden cluster, hierarchical clustering identified symptom phenotypes. Results Of 1,787 infected participants, 511 met criteria (22% ≥50 years; 55% female; 60% White non-Hispanic; 54% mental health disorder; 7.2% immunodeficiency; 21% ≥2 comorbidities; 30% prior infection; 24% never vaccinated pre-index). Three clusters emerged: highest, moderate, and lowest burden. The highest-burden cluster (median 6 symptoms at 6 and 9 months) was characterized by fatigue (57%–74%), concentration difficulty, post-exertional malaise, myalgia, sleep disturbance, gastrointestinal symptoms, headache, irritability, and mobility limitations (each ∼46%–53%). The moderate cluster peaked at 3 symptoms (fatigue 42%); the lowest remained ∼1 symptom (fatigue 24% at 12 months). Older age (aOR 2.68, 95% CI 1.59–4.53), female sex (2.36, 1.48–3.76), mental health disorder (2.65, 1.65–4.25), and immunodeficiency (4.23, 1.71–10.51) were associated with highest vs lowest burden. Within the highest-burden cluster, three phenotypes emerged: neurological/multisystemic, psychiatric/neurological, and physical/respiratory. Conclusions Distinct long-COVID clusters and phenotypes underscore heterogeneity and support tailored management and risk stratification.

  • Open Access

    Natural History of Self-reported Symptoms Following SARS-CoV-2 Infection: A Target Trial Emulation in a Prospective Community-Based Cohort

    by Yanhan Shen, Zach Shahn, Mckaylee Robertson, Kelly Gebo, Denis Nash

    Background The natural history of symptoms after SARS-CoV-2 infection remains uncertain because many studies are non-representative, ignore background symptom prevalence, lack longitudinal tracking, and omit appropriate controls. Using a prospective, community-based cohort with repeated symptom measures, we estimated post-infection risks of long COVID symptoms versus contemporaneous uninfected controls. Methods We analyzed the CHASING COVID Cohort, a U.S. longitudinal study with surveys and serology (March 2020–December 2023). Infection status (January 2021–December 2022) was determined from self-reported PCR/antigen results, serology, or CSTE probable criteria. We emulated 24 monthly target trials comparing individuals newly infected at time zero with those remaining uninfected. Outcomes were new-onset long-COVID symptoms not reported pre-infection, assessed overall and within three clusters (neurological, autonomic, exercise intolerance) at 4–8 and 9–12 months post-infection. Inverse probability of treatment and censoring weights adjusted for confounding and informative loss to follow-up. Results The analysis included 1,055 infected and 52,310 uninfected person-trials. At 4–8 months, the adjusted risk of any long-COVID symptom was 22.6% (95% CI, 20.5–24.8) among infected versus 11.3% (11.1–11.5) among uninfected (adjusted risk difference [aRD], 11.3% [9.2–13.5]; adjusted risk ratio [aRR], 2.01 [1.81–2.20]). At 9–12 months, risks were 19.2% (17.0–21.3) vs 12.4% (12.2–12.7) (aRD, 6.7% [4.6–8.9]; aRR, 1.54 [1.37–1.72]). Across all three clusters, infected participants had consistently higher risks at both intervals. Conclusions SARS-CoV-2 infection was associated with elevated risk of new-onset long-COVID symptoms persisting up to 12 months. Using a national community-based cohort, contemporaneous uninfected controls, and target-trial emulation clarifies the burden attributable to infection and supports ongoing surveillance and targeted prevention and care.

  • Open Access

    Testing Theory-Enhanced Messaging to Promote COVID-19 Vaccination Among Adults: Randomized Controlled Trial

    by Rachael Piltch-Loeb, Yanhan Shen, Sasha Fleary, McKaylee Robertson, Josefina Nuñez Sahr, Kate Penrose, Jenna Sanborn, Surabhi Yadav, Avantika Srivastava, Denis Nash, et al.

    Background: Uptake of the COVID-19 vaccine has been low in the United States despite ongoing public health recommendations. This has been linked to many factors, including pandemic fatigue; reduced risk perception; dis- and misinformation; and, more recently, symptoms of depression and anxiety. Novel communication and messaging strategies are one potential approach to promote vaccine uptake. Objective: This randomized controlled trial aimed to fill research gaps by testing the effect of 2 communication-based approaches―the use of a short attitudinal inoculation message and cognitive behavioral therapy (CBT) kernel messaging―compared to standard public health messaging on vaccine uptake in a cohort of adult US residents. Methods: We completed a 3-arm, parallel-group, assessor-blinded stratified randomized trial between April 15, 2024, and May 2, 2024. Individuals were eligible if they were aged ≥18 years and (1) had received at least one dose of the COVID-19 vaccine but (2) had not received COVID-19 vaccine doses since September 11, 2023, and (3) had not been infected with SARS-CoV-2 in the previous 3 months. We purposively sampled eligible individuals with and without symptoms of anxiety and depression. Participants were randomly allocated to the (1) attitudinal inoculation intervention, (2) CBT kernel intervention, or (3) standard public health messaging intervention. Results: By the 4-week follow-up, COVID-19 vaccination uptake was low overall (17/1403, 1.2%, 95% CI 0.6%-1.8%) and did not significantly differ by study arm―1.5% (7/469) in the CBT kernel arm (95% CI 0.4%-2.8%), 0.9% (4/466) in the inoculation arm (95% CI 0%-1.8%), and 1.3% (6/468) in the standard arm (95% CI 0.3%-2.4%). Compared to the standard arm, the CBT kernel intervention yielded a risk difference (RD) of 0.3% (95% CI −1.3% to 1.8%) and a risk ratio (RR) of 1.21 (95% CI 0.41-3.59); the inoculation intervention yielded an RD of −0.4% (95% CI −1.8% to 1%) and an RR of 0.69 (95% CI 0.19-2.44). Reported SARS-CoV-2 infections and vaccine uptake did not differ by anxiety or depression symptoms. At baseline, approximately one-third of participants (466/1403, 33.21%) reported high willingness to receive another COVID-19 vaccine dose, with no significant differences across arms. At the 4-week follow-up, willingness remained similar across groups (CBT kernel vs standard arm: RD=−0.3%, 95% CI −6.3% to 5.8%, and RR=0.99, 95% CI 0.79-1.25; inoculation vs standard arm: RD=7%, 95% CI 0.8%-13.3%, and RR=1.23, 95% CI 0.98-1.53). Willingness did not differ by mental health status. Conclusions: Successful efforts to increase uptake of the COVID-19 vaccine via theory-enhanced messaging remain elusive. Findings underscore the challenges of shifting behavior through messaging alone in a context of declining public trust and a diminished sense of urgency years after the onset of the COVID-19 pandemic. Ongoing research is needed to better understand and address informational and behavioral barriers to vaccination. Trial Registration: ClinicalTrials.gov NCT06119854; https://clinicaltrials.gov/study/NCT06119854


  • Open Access

    Testing Theory-Enhanced Messaging to Promote COVID-19 Vaccination Among Adults: Randomized Controlled Trial (Preprint)

    by Rachael Piltch-Loeb, Yanhan Shen, Sasha Fleary, McKaylee Robertson, Josefina Nuñez Sahr, Kate Penrose, Jenna Sanborn, Surabhi Yadav, Avantika Srivastava, Denis Nash, et al.

    BACKGROUND Uptake of the COVID-19 vaccine has been low in the United States despite ongoing public health recommendations. This has been linked to many factors, including pandemic fatigue; reduced risk perception; dis- and misinformation; and, more recently, symptoms of depression and anxiety. Novel communication and messaging strategies are one potential approach to promote vaccine uptake. OBJECTIVE This randomized controlled trial aimed to fill research gaps by testing the effect of 2 communication-based approaches―the use of a short attitudinal inoculation message and cognitive behavioral therapy (CBT) kernel messaging―compared to standard public health messaging on vaccine uptake in a cohort of adult US residents. METHODS We completed a 3-arm, parallel-group, assessor-blinded stratified randomized trial between April 15, 2024, and May 2, 2024. Individuals were eligible if they were aged ≥18 years and (1) had received at least one dose of the COVID-19 vaccine but (2) had not received COVID-19 vaccine doses since September 11, 2023, and (3) had not been infected with SARS-CoV-2 in the previous 3 months. We purposively sampled eligible individuals with and without symptoms of anxiety and depression. Participants were randomly allocated to the (1) attitudinal inoculation intervention, (2) CBT kernel intervention, or (3) standard public health messaging intervention. RESULTS By the 4-week follow-up, COVID-19 vaccination uptake was low overall (17/1403, 1.2%, 95% CI 0.6%-1.8%) and did not significantly differ by study arm―1.5% (7/469) in the CBT kernel arm (95% CI 0.4%-2.8%), 0.9% (4/466) in the inoculation arm (95% CI 0%-1.8%), and 1.3% (6/468) in the standard arm (95% CI 0.3%-2.4%). Compared to the standard arm, the CBT kernel intervention yielded a risk difference (RD) of 0.3% (95% CI −1.3% to 1.8%) and a risk ratio (RR) of 1.21 (95% CI 0.41-3.59); the inoculation intervention yielded an RD of −0.4% (95% CI −1.8% to 1%) and an RR of 0.69 (95% CI 0.19-2.44). Reported SARS-CoV-2 infections and vaccine uptake did not differ by anxiety or depression symptoms. At baseline, approximately one-third of participants (466/1403, 33.21%) reported high willingness to receive another COVID-19 vaccine dose, with no significant differences across arms. At the 4-week follow-up, willingness remained similar across groups (CBT kernel vs standard arm: RD=−0.3%, 95% CI −6.3% to 5.8%, and RR=0.99, 95% CI 0.79-1.25; inoculation vs standard arm: RD=7%, 95% CI 0.8%-13.3%, and RR=1.23, 95% CI 0.98-1.53). Willingness did not differ by mental health status. CONCLUSIONS Successful efforts to increase uptake of the COVID-19 vaccine via theory-enhanced messaging remain elusive. Findings underscore the challenges of shifting behavior through messaging alone in a context of declining public trust and a diminished sense of urgency years after the onset of the COVID-19 pandemic. Ongoing research is needed to better understand and address informational and behavioral barriers to vaccination. CLINICALTRIAL ClinicalTrials.gov NCT06119854; https://clinicaltrials.gov/study/NCT06119854